|Bid||68.85 x 900|
|Ask||82.28 x 1300|
|Day's Range||69.29 - 72.48|
|52 Week Range||38.41 - 79.81|
|Beta (5Y Monthly)||0.41|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 23, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||70.63|
Does Axonics Modulation Technologies (AXNX) have what it takes to be a top stock pick for momentum investors? Let's find out.
IRVINE, Calif., August 05, 2022--Axonics, Inc. (Nasdaq: AXNX) ("Axonics"), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the closing of its public offering of 2,012,500 shares of its common stock at a price of $63.85 per share to the underwriter, which includes the exercise in full by the underwriter of its option to purchase 262,500 additional shares. The gross proceeds from the offer
Here is how Axonics Modulation Technologies (AXNX) and Dynavax Technologies (DVAX) have performed compared to their sector so far this year.